Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,193.6
-8.3 (-0.26%)

 

  • STI Straits Times Index
    3,193.6
    -8.3 (-0.26%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,586.2
    -1.8 (-0.11%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,132.0
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,609.9
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,105.1
    504.7 (1.76%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,625.7
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 257.0M
  • Value: 136.7M
  • Rise: 94
  • Fall: 71
  • Unch: 586

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Jiutian Chemical0.091+0.002
Hatten Land0.065+0.002
Beverly JCG0.001-
Mermaid Maritime0.107+0.011
Sinjia Land0.103+0.003
Net Pacific Fin0.036+0.002
QT Vascular0.006+0.001
Thomson Medical0.088-0.001
ThaiBev0.710-
Rex Intl0.355-0.005

World Indices

World Indices
Name Last Change
Nasdaq 15,226.7 +136.5
HSI 26,201.0 +68.9
HSCEI 9,343.5 +21.4
Jakarta 6,625.7
Nikkei 225 29,138.2 +537.8
SSE Comp 3,622.2 +12.4
Shanghai A 3,796.3 +13.0
Shanghai B 277.3 +0.6
KOSPI 3,036.6 +16.0

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

PYC THERAPEUTICS LIMITED PYC THERAPEUTICS
Updated on 25 Oct 2021 (End of trading day)
Last (AUD): 0.140 Change: -0.005 High: 0.145 Remarks: -
Change (%): -3.45 Low: 0.140
Open 0.145 Yesterday's Close 0.14500000000000002
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 227,570 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (AUD) a -0.00559 Trailing EPS (AUD) e -0.00559 NAV (AUD) b 0.0167
PE a - Trailing PE f - Price / NAV b 8.3832
Dividend (AUD) d - Cash In Hand (AUD) g 0.0058 Issued & Paid-up Shares c 3,180,930,000
Dividend Yield (%) d - Price / Cash In Hand g 24.138 Treasury Shares h -
Beta - 75 Daysi 0.606 R-Squared - 75 Days(%)i 1.44 Market Cap (M) 445.330
Beta - 500 Daysi 0.247 R-Squared - 500 Days (%)i 0.11 Enterprise Value (M) 395.439
Piotroski F Score 1 Exchange Code PYC Par Value ( AUD ) n.a.
52 Weeks Volatility (%) 39.22 Free Float (%) 34.4
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 15 Jun 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 30 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference PYC THERAPEUTICS LIMITED ASX 445.330 - - 8.3832 -
Industry Pharmaceuticals: Major ASX 132.785 - - 7.0803 -
Local Peer RACE ONCOLOGY LTD ASX 480.668 - - 35.0427 -
Local Peer STARPHARMA HOLDINGS LIMITED ASX 438.737 - - 7.0404 -
Local Peer AFT PHARMACEUTICALS LTD ASX 408.287 57.573 57.577 12.1344 -
Local Peer RECCE PHARMACEUTICALS LTD ASX 165.089 - - 8.0508 -
Local Peer NOXOPHARM LTD ASX 160.731 - - 3.9427 -
Local Peer CRESO PHARMA LTD ASX 132.388 - - 4.9327 -
Local Peer EXOPHARM LTD ASX 84.108 - - 4.4583 -
Local Peer INVION LTD ASX 76.243 - - 16.2500 -
Local Peer MEDLAB CLINICAL LIMITED ASX 53.037 - - 3.4989 -
Local Peer PALLA PHARMA LTD ASX 57.479 - - 2.8652 -
Local Peer PHARMAXIS ASX 52.247 - - 18.2540 -
Local Peer ONCOSIL MEDICAL LIMITED ASX 40.409 - - 3.4459 -
Other Local Peers ACRUX (ASX), IMMURON LIMITED (ASX), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), SUDA PHARMACEUTICALS LTD (ASX), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX)
Global Peer JOHNSON & JOHNSON NYSE 431,937.318 29.356 24.158 - 2.426
Global Peer PFIZER INC NYSE 241,928.674 25.159 18.289 3.4540 3.521
Global Peer ELI LILLY AND COMPANY NYSE 234,410.174 37.847 38.613 36.3743 1.208
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 202,933.251 25.140 22.588 3.7551 2.312
Global Peer MERCK & CO INC NYSE 206,711.674 29.250 37.105 6.2087 3.036
Global Peer ABBVIE INC NYSE 191,739.030 42.085 29.100 15.2548 4.456
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 191,380.138 59.881 50.751 12.2085 1.879
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 188,192.695 29.205 26.435 18.0001 1.267
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 128,460.179 - - 3.4900 3.214
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 125,816.343 8.963 18.168 1.6777 2.719
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC CO LTD (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), VIATRIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), HANSOH PHARMACEUTICAL GROUP CO LTD (HKEx), INNOVENT BIOLOGICS INC (HKEx), CANSINO BIOLOGICS INC (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), ORGANON & CO (NYSE), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), SINOPHARM GROUP CO. LTD. (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), CUREVAC NV (NASDAQ), REMEGEN CO LTD (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), ALLAKOS INC (NASDAQ), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), HUTCHMED (CHINA) LIMITED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), AKESO INC (HKEx), SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), INNOCARE PHARMA LTD (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), NEKTAR THERAPEUTICS (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CHINA GRAND PHARMACEUTICAL & HEALTH (HKEx), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), OPKO HEALTH INC (NASDAQ), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), ATAI LIFE SCIENCES NV (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), ERASCA INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), ADC THERAPEUTICS SA (NYSE), EVEREST MEDICINES LTD (HKEx), QUANTERIX CORPORATION (NASDAQ), SHANGHAI HENLIUS BIOTECH INC (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), IGM BIOSCIENCES INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP LIMITED (HKEx), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), CSTONE PHARMACEUTICALS (HKEx), OCUMENSION THERAPEUTICS (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), UNITED LABORATORIES INTL HLDGS LTD (HKEx), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), PROCAPS GROUP S A (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), IMMUNOTECH BIOPHARM LTD (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), ZYMEWORKS INC (NYSE), ATEA PHARMACEUTICALS INC (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), ABBISKO CAYMAN LTD (HKEx), Kimia Farma Tbk. (IDX), ICOSAVAX INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), KRONOS BIO INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), CK LIFE SCIENCES INTL HLDG (HKEx), TENAYA THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ANTENGENE CORP LTD (HKEx), MIND MEDICINE (MINDMED) INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), PETIQ INC (NASDAQ), ANNEXON INC (NASDAQ), GH RESEARCH PLC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), POINT BIOPHARMA GLOBAL INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), BEYONDSPRING INC (NASDAQ), TRANSCENTA HOLDING LTD (HKEx), ORIC PHARMACEUTICALS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), GRITSTONE BIO INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), HUA MEDICINE (HKEx), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), PHARVARIS NV (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), MIRUM PHARMACEUTICALS INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), EVOLUS INC (NASDAQ), AC IMMUNE SA (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), IGBB (Bursa), EVELO BIOSCIENCES INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), PROVENTION BIO INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CLENE INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), THERATECHNOLOGIES INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), TOT BIOPHARM INTL CO LTD (HKEx), CODIAK BIOSCIENCES INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), CYBIN INC (NYSE American), FUSION PHARMACEUTICALS INC (NASDAQ), BSTEAD (Bursa), NEXIMMUNE INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), XOMA CORP (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), ATHENEX INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), DURECT CORP (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), PHARMA (Bursa), TCR2 THERAPEUTICS INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), FUSEN PHARMACEUTICAL CO LTD (HKEx), OVID THERAPEUTICS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), ANNOVIS BIO INC (NYSE American), GAMIDA CELL LTD (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), IMMUNIC INC (NASDAQ), OBSEVA SA (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), TRICIDA INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), MUSTANG BIO INC (NASDAQ), IP (SET), PHASEBIO PHARMACEUTICALS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), ALZAMEND NEURO INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), EYENOVIA INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), HOOKIPA PHARMA INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), POLYPID LTD (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), NOVAN INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), IX Biopharma (SGX), AYALA PHARMACEUTICALS INC (NASDAQ), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), LOGICBIO THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), LANTERN PHARMA INC (NASDAQ), GENPREX INC (NASDAQ), LANNETT CO INC (NYSE), KOTRA (Bursa), DARE BIOSCIENCE INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), MEDIWOUND LTD (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), CHARMACY PHARMACEUTICAL CO LTD (HKEx), IMARA INC (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), GALECTO INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), MANNATECH INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), Phapros Tbk. (IDX), OCUPHIRE PHARMA INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), NOVA (Bursa), PAK FAH YEOW INTERNATIONAL (HKEx), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), Hyphens Pharma (SGX), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), BIOHLDG (Bursa), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), RENOVORX INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), BONE BIOLOGICS CORP (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), BAUDAX BIO INC (NASDAQ), PURAPHARM CORPORATION LIMITED (HKEx), SEQLL INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), XORTX THERAPEUTICS INC (NASDAQ), DERMATA THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), ACER THERAPEUTICS INC (NASDAQ), JCT (SET), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), SUNZEN (Bursa), NLS PHARMACEUTICS LTD (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), PAINREFORM LTD (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), PETROS PHARMACEUTICALS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.015
-9.68 %
10 Days ---
20 Days -+0.005
+3.70 %
Medium Term Return 3 Months --0.010
-6.67 %
6 Months --0.030
-17.65 %
1 Year --0.030
-17.65 %
Long Term Return 2 Years -+0.075
+115.38 %
3 Years -+0.108
+337.50 %
5 Years -+0.123
+723.53 %
Annualised Return Annualised --
+52.45 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.110 - 0.190 Change From 1 Year Low +0.030 % Change From 1 Year Low (%) +27.27
Change From 1 Year High -0.050 % Change From 1 Year High (%) -26.32
2 Years Range 0.043 - 0.205 Change From 2 Years Low +0.097 % Change From 2 Years Low (%) +225.58
Change From 2 Years High -0.065 % Change From 2 Years High (%) -31.71
5 Years Range 0.015 - 0.205 Change From 5 Years Low +0.125 % Change From 5 Years Low (%) +852.38
Change From 5 Years High -0.065 % Change From 5 Years High (%) -31.71
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. The company was founded by Richmond Miles Hopkins and Paul Michael Watt on October 9, 2001 and is headquartered in Nedlands, Australia.

Historical Price Data

Date Open High Low Close Volume VWAP
25 Oct 2021 0.145 0.145 0.140 0.140 227,570 -
22 Oct 2021 0.140 0.145 0.140 0.145 32,158 -
21 Oct 2021 0.145 0.145 0.140 0.140 119,305 -
20 Oct 2021 0.147 0.150 0.145 0.145 572,211 -
19 Oct 2021 0.155 0.155 0.145 0.145 186,118 -
18 Oct 2021 0.145 0.155 0.142 0.155 2,398,607 -
15 Oct 2021 0.135 0.145 0.135 0.145 2,525,967 -
14 Oct 2021 0.135 0.137 0.135 0.135 525,200 -
13 Oct 2021 0.140 0.140 0.137 0.140 67,675 -
12 Oct 2021 0.140 0.140 0.137 0.140 473,476 -
11 Oct 2021 0.140 0.145 0.135 0.140 196,994 -
08 Oct 2021 0.140 0.145 0.135 0.145 286,783 -
07 Oct 2021 0.145 0.145 0.140 0.140 170,267 -
06 Oct 2021 0.135 0.145 0.135 0.145 387,482 -
05 Oct 2021 0.145 0.145 0.140 0.140 224,947 -
04 Oct 2021 0.140 0.145 0.140 0.140 487,357 -
01 Oct 2021 0.140 0.145 0.137 0.140 580,837 -
30 Sep 2021 0.140 0.140 0.140 0.140 208,341 -
29 Sep 2021 0.145 0.145 0.140 0.140 185,057 -
28 Sep 2021 0.135 0.145 0.135 0.145 443,688 -
27 Sep 2021 0.135 0.145 0.135 0.135 66,302 -
24 Sep 2021 0.135 0.140 0.135 0.140 28,366 -
Summary
Current 2 Weeks
(12 Oct 2021 to 25 Oct 2021)
0.140 0.155 0.135 0.140 7,128,287 -
Previous 2 Weeks
(28 Sep 2021 to 11 Oct 2021)
0.135 0.155 0.135 0.140 3,171,753 -
4 Weeks from
(31 Aug 2021 to 27 Sep 2021)
0.150 0.155 0.135 0.135 11,951,374 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.